| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $113.3M | +25.1% |
| SG&A Expense | $47.9M | +36.6% |
| Operating Income | -$161.2M | -28.3% |
| Net Income | -$157.0M | -24.9% |
| EPS (Basic) | -$5.30 | +26.0% |
| EPS (Diluted) | -$5.30 | +26.0% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $5.4M | -87.9% |
| Short-term Investments | $142.9M | -14.7% |
| Accounts Receivable | $512K | — |
| Current Assets | $152.9M | -31.5% |
| Total Assets | $152.9M | -31.5% |
| Current Liabilities | $12.5M | -17.2% |
| Total Liabilities | $12.5M | -17.2% |
| Line Item | 2022-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$103.8M | -13.0% |
| Investing Cash Flow | $19.7M | +136.5% |
| Financing Cash Flow | $45.0M | -76.0% |
| Stockholders' Equity |
| $140.4M |
| -32.6% |